Online inquiry

IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A))   (CAT#: GTTS-WQ1070MR)

This product GTTS-WQ1070MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets SLAMF7 gene. The antibody can be applied in Multiple myeloma (MM) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Chimeric; Humanized
RefSeq NM_001282588.2
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 57823
UniProt ID Q9NQ25
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-SLAMF7, ABBV-838(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) (GTTS-WQ1070MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ9542MR IVTScrip™ mRNA-Anti-TNFRSF17, J6M0(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA J6M0
GTTS-WQ842MR IVTScrip™ mRNA-Anti-CD276, ABBV-155(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA ABBV-155
GTTS-WQ3303MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA ASN-100
GTTS-WQ1467MR IVTScrip™ mRNA-Anti-CD22, ACD22-VCMMAE(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA ACD22-VCMMAE
GTTS-WQ776MR IVTScrip™ mRNA-Anti-LOXL2, AB0024(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA AB0024
GTTS-WQ5249MR IVTScrip™ mRNA-Anti-S, CB-6(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA CB-6
GTTS-WQ2010MR IVTScrip™ mRNA-Anti-INSR, AGT-181(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA AGT-181
GTTS-WQ10356MR IVTScrip™ mRNA-Anti-APP, LY2062430(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA LY2062430
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW